This company has shut down. Icosavax is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardIcosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Icosavax has raised $67.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Icosavax's investors include RA Capital Management, Cormorant Asset Management, Adams Street Partners, Vivo Capital, Bill & Melinda Gates Foundation.
Icosavax is headquartered in Seattle, United States.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Icosavax is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Icosavax — Funding & Investors." VCBacked, May 22, 2023, https://www.vcbacked.co/company/icosavax. Accessed July 19, 2026.
VCBacked. (2023). Icosavax — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/icosavax
{{cite web |title=Icosavax — Funding & Investors |url=https://www.vcbacked.co/company/icosavax |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated